CN102327275B - Application of 3-[4-(sulfonyl)benzene] urea compound in preparation of medicine for tumour - Google Patents
Application of 3-[4-(sulfonyl)benzene] urea compound in preparation of medicine for tumour Download PDFInfo
- Publication number
- CN102327275B CN102327275B CN 201110263951 CN201110263951A CN102327275B CN 102327275 B CN102327275 B CN 102327275B CN 201110263951 CN201110263951 CN 201110263951 CN 201110263951 A CN201110263951 A CN 201110263951A CN 102327275 B CN102327275 B CN 102327275B
- Authority
- CN
- China
- Prior art keywords
- benzene
- sulphonyl
- phenyl
- cell
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses the application of 3- [4- (sulphonyl) benzene] carbamide compounds or its pharmaceutical salt in preparation anti-lung cancer, anti-breast cancer medicines, and wherein the chemical structural formula of 3- [4- (sulphonyl) benzene] carbamide compounds is as shown in following general formula:
In formula, X is O or S; R1 is aromatic group or mono-substituted benzaldehyde base containing 1 phenyl ring
Wherein R4 is halogen; R2 and R3 can be respectively selected from: hydrogen, the alkyl of C1~C4, C6~C8 the phenyl containing 1~2 substituent group or
Present invention firstly discovers that 3- [4- (sulphonyl) benzene] carbamide compounds or its pharmaceutical salt have the function of ROCK inhibitor, the proliferation of lung carcinoma cell, breast cancer cell is significantly inhibited, may be used as the drug of preparation anti-lung cancer, anti-breast cancer.
Description
Technical field
The present invention relates to a kind of 3-[4-(sulphonyl) benzene] carbamide compounds and the application in the preparation antitumor drug thereof.
Background technology
Cancer is that malignant tumor is the No.1 killer of present human health.The statistical data of Ministry of Public Health announcement in 2010 shows that malignant tumor has become the Chinese primary cause of the death.Therefore, the treatment of cancer is very urgent.Cancer is the process of a multi-step, relates generally to the variation of a plurality of genes; When the gene of regulating cell growth is undergone mutation or is damaged, the programmed death of cell is suppressed, so that cell is out of hand, the growth that continues and division and produce tumor can be accelerated the formation of tumor neogenetic blood capillary simultaneously in the infiltration of these cancerous cell and the transfer process.In the most general genovariation, what cause these defectives is the abnormal activation of GTP enzyme Ras family.The sudden change of Ras albumen is found to occur in 30% the human tumor, and the Rho family protein is the member of the super family of Ras of small G-protein, has the GTP enzymatic activity.
Rho kinases (ROCKs) belongs to the serine/threonine protein kitase of AGC family, it is first found Rho downstream effect factor, by the impact of phosphorylation light chain having been regulated the variation of the myosin cytoskeleton that RhoA induces.Studies show that the various aspects of Rho family protein and tumor development all are related, comprise the growth of tumor and propagation, invasion and attack and transfer, apoptosis, tumor neovasculature formation etc.What Rho protein continued in human tumor is activated, uncontrolled propagation, invasion and attack body and vicious transformation.Because the effect of Rho/ROCK signal in tumor cell proliferation, differentiation and motion becomes the focus that people pay close attention to so that treat some tumor that has Rho signal excessive activation by blocking-up ROCK signal.ROCK is divided into two kinds of ROCK I and ROCK II.The overexpression of ROCK is or/and highly activate the generation all can cause disease, and associated disease mainly comprises cardiovascular disease, nervous system disease, fibrotic disease and tumor etc.At anti-tumor aspect, but all find invasion and attack and the transfer of ROCK inhibitor inhibition tumor cell in the research of people on hepatoma carcinoma cell, ovarian cancer cell, hepatoma carcinoma cell, lung cancer cell line, breast carcinoma cell strain, bladder cell strain etc.
Aspect antitumor drug research, external many pharmaceuticals and scientific research institution are developing the new ROCK inhibitor with antitumous effect.At present, although there are some ROCK inhibitor to enter I phase or II phase clinical research stage (such as BA-210), the ROCK inhibitor that success is gone on the market only has one, namely method Soviet Union ground you (Fasudil), and only limit to the Japanese market.Therefore, actively seek and design new ROCK inhibitor, and explore its anticancer effect, have important clinical meaning and wide application prospect.
Summary of the invention
Goal of the invention of the present invention provides a kind of 3-[4-(sulphonyl) benzene] carbamide compounds is in the application of preparation ROCK inhibitor.
To achieve the above object of the invention, the technical solution used in the present invention is: 3-[4-(sulphonyl) benzene] carbamide compounds, its chemical structural formula is shown in following general formula:
In the formula, X is O or S;
R
1Be aromatic group or the mono-substituted benzaldehyde base that contains 1 phenyl ring
R wherein
4Be halogen;
R
2And R
3Can be selected from respectively: the alkyl of hydrogen, C1~C4, C6~C8 contain 1~2 substituent phenyl or
In the preferred technical scheme, work as R
1When containing the aromatic group of 1 phenyl ring, R
1Be preferably the aromatic group that contains 1~2 substituent C6~C8 on the phenyl ring, the described substituent group on the phenyl ring can be selected from respectively: hydrogen, halogen, hydroxyl, amino, methyl, trifluoromethyl,
In the preferred technical scheme, R
2And R
3Be selected from respectively: the alkyl of hydrogen, C1~C2, C6~C8's contains 1~2 substituent phenyl, and described substituent group is halogen or methyl.
In the preferred technical scheme, R
1For containing the phenyl of 2 halogenic substituents, R
2Be hydrogen, R
3Alkyl for C1~C4.
Again in another preferred technical scheme, described 3-[4-(sulphonyl) benzene] carbamide compounds is selected from: 1-(3-chlorine 4-fluorophenyl)-3-[4-(N-sulfonyloxy methyl amido) phenyl] urea, 1-(2-bromo-4 chloro-phenyl)-3-[4-[(4-aminomethyl phenyl) sulfonamides] phenyl] thiourea, 1-(2-trifluoromethyl)-3-[4-[(4-aminomethyl phenyl) sulfonamides] phenyl] thiourea, 1-(2, the 3-Dichlorobenzene base)-and 3-[4-(N-ethyl sulfonamide base) phenyl] urea, 1-(2, the 4-difluorophenyl)-and 3-[4-(N-benzoyl sulfoamido) phenyl] urea, 1-(4-acetylphenyl)-3-[4-[N-(3,5-Dichlorobenzene base sulfoamido)] phenyl] urea, 1-(2-aminomethyl phenyl)-3-[2-methyl 5-(sulfoamido) phenyl] urea, 1-(4-chloro phenyl)-3-[4-(N-tert-butyl group sulfoamido) phenyl] urea, 1-(3-chlorphenyl)-3-[4-(N, N-dimethyl methyl amide groups) phenyl] urea, 1-(2-chloro-benzoyl)-3-[4-[(N, the N-aminomethyl phenyl) sulfoamido] phenyl] thiourea; Its chemical structural formula is followed successively by:
Above-mentioned 3-[4-(sulphonyl) benzene] the urea groups analog derivative is commodity.
The present invention is to above-mentioned 3-[4-(sulphonyl) benzene] the urea groups analog derivative further carried out Determination of biological activity, it is active to find that they all have an obvious inhibition to ROCK1, for breast carcinoma and lung carcinoma cell in various degree fragmentation effect is arranged at cellular level.
Therefore; the present invention is claimed above-mentioned 3-[4-(sulphonyl) benzene simultaneously] carbamide compounds or its pharmaceutically useful salt are in the application of preparation ROCK inhibitor, and described pharmaceutically useful salt comprises hydrochlorate, phosphate, sulfate, acetate, maleate, citrate, benzene sulfonate, toluenesulfonate, fumarate, tartrate.
The present invention is claimed above-mentioned 3-[4-(sulphonyl) benzene simultaneously] carbamide compounds or the application of its pharmaceutically useful salt in the anti-pulmonary carcinoma of preparation, breast cancer medicines.
Because technique scheme is used, the present invention compared with prior art has following advantages:
1. the present invention has found 3-[4-(sulphonyl) benzene first] carbamide compounds or its pharmaceutically useful salt possesses the function of ROCK inhibitor, propagation to lung carcinoma cell, breast cancer cell has obvious inhibitory action, can be as the medicine of the anti-pulmonary carcinoma of preparation, anti-breast cancer.
Description of drawings
Inhibitor is to the inhibition curve of ROCK1 among Fig. 1 embodiment one;
Inhibitor is to the fragmentation effect of HeLa cell among Fig. 2 embodiment one;
Inhibitor is to the fragmentation effect of H460 lung carcinoma cell among Fig. 3 embodiment one;
Inhibitor is to the fragmentation effect of MDA-231 breast cancer cell among Fig. 4 embodiment one.
The specific embodiment
The invention will be further described below in conjunction with drawings and Examples:
Embodiment one: analyze 1-(3-chlorine 4-fluorophenyl)-3-[4-(N-sulfonyloxy methyl amido) phenyl] urea
The enzyme inhibition activity experiment of ROCK1.The enzyme inhibition activity experiment of ROCK1
Experimental principle: compound R OCK1 suppresses active measurement and has adopted the Z ' of Invitrogen company-LYT technology, this technology is based on FRET (fluorescence resonance energy transfer) (FRET) principle, take phosphorylation and non-phosphorylating polypeptide to the sensitivity differences of Proteolytic enzyme cutting as the basis.
Experimental technique:
(1) preparation of reagent.Kinase buffer liquid: the 5X kinase buffer liquid of 2ml is diluted with water to 10ml; Chemical compound: the chemical compound that test is diluted with water to a Concentraton gradient; The mixed solution of ROCK kinases/substrate: the mixed solution of preparing the ROCK/ substrate of 2250 μ L; The concentration of enzyme is 10ng/ml, and the concentration of substrate is 4 μ M, and solvent is kinase buffer liquid; MALDI-PSD solution: serine/threonine phosphorylation 7 peptides of 2 μ L are added in the kinase buffer liquid of 498 μ L, fully mixing; ATP solution: the ATP solution of preparing 1110 μ L.Concentration is 50 μ M, and solvent is kinase buffer liquid; Developer: by 1: 32768 dilution proportion developer A.
(2) experimental procedure: 1. the compound solution that 2.5 μ L is prepared is added to black 384 orifice plates; 2. the mixed solution that adds ROCK kinases/substrate of 5 μ L; 3. the ATP solution that adds 2.5 μ L; 4. 384 orifice plates are at room temperature shaken and cultivated 1 hour; 5. add 5 μ L developers in orifice plate, continue reaction 1 hour; 6. orifice plate is placed the microplate reader reading.
Experimental result: the 1-of variable concentrations (3-chlorine 4-fluorophenyl)-3-[4-(N-sulfonyloxy methyl amido) phenyl] urea carries out the enzyme inhibition activity experiment of ROCK 1, finds that this chemical compound has good ROCK1 to suppress active, its 503nhibiting concentration IC
50Be 8.4 μ M/L (such as Fig. 1).
(3) cellular sensitivity experiment
Experimental principle: the MTT analytic process utilizes microplate reader to measure the optical density OD value at 490nm place take living cells metabolite Reducing agent MTT tetrazolium bromide as the basis, and reflecting the living cells number, thereby the mensuration chemical compound is to the fragmentation effect of tumor cell.
Experimental procedure: 1. collect the logarithmic (log) phase cell, adjust concentration of cell suspension, every hole adds 100 μ L, bed board make cell density to be measured be 1000-10000/hole (edge hole is filled with aseptic PB S); 2. 96 orifice plates are placed on 5%CO2, hatch in 37 ℃ of incubators, be paved with the hole to cell monolayer at the bottom of, add the medicine of Concentraton gradient.In principle, get final product dosing behind the cell attachment, or two hours, or time half a day, but we are everlasting evening before that day bed board, dosing in morning next day.General 5-7 gradient, every hole 5 μ L establish 3-5 parallel hole; 3.5%CO2 was hatched 16-48 hour, and was observed under the inverted microscope for 37 ℃; 4. every hole adds the MTT solution (5mg/ml, i.e. 0.5%MTT) of 20 μ L, continues to cultivate 4h.If medicine and MTT can react, discard culture fluid after can be first centrifugal, carefully with PB S rush 2-3 all over after, add again the culture fluid that contains MTT; 5. stop cultivating, carefully suck culture fluid in the hole; 6. every hole adds 150 μ L dimethyl sulfoxide, puts low-speed oscillation 10min on the shaking table, and crystal is fully dissolved.Measure the light absorption value in each hole at enzyme-linked immunosorbent assay instrument OD=490nm place.And ROCK1 crosses high expressed in multiple cancerous cell, so the anticancer cytoactive that we attempt this chemical compound with multiple cancerous cell, the cancerous cell of use have H460, HepG-2, A549,7721, K562, KB, MCF-7, MDA-231, Lp 1 and OPM-2.Determine the toxicity size of this kind chemical compound by the HeLa cell experiment.
Experimental result: the HeLa cytotoxicity of this inhibitor lower (Fig. 2).In addition, chemical compound shows obvious inhibition to the propagation of lung carcinoma cell H460 and breast cancer cell MDA-231, can kill the cancerous cell (Fig. 3 and 4) of half under lower concentration.
Claims (1)
1. 3-[4-(sulphonyl) benzene] carbamide compounds or the application of its pharmaceutically useful salt in the anti-pulmonary carcinoma of preparation, anti-breast cancer medicines, wherein 3-[4-(sulphonyl) benzene] carbamide compounds is 1-(3-chlorine 4-fluorophenyl)-3-[4-(N-sulfonyloxy methyl amido) phenyl] urea.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110263951 CN102327275B (en) | 2011-09-07 | 2011-09-07 | Application of 3-[4-(sulfonyl)benzene] urea compound in preparation of medicine for tumour |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110263951 CN102327275B (en) | 2011-09-07 | 2011-09-07 | Application of 3-[4-(sulfonyl)benzene] urea compound in preparation of medicine for tumour |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102327275A CN102327275A (en) | 2012-01-25 |
CN102327275B true CN102327275B (en) | 2013-03-20 |
Family
ID=45479407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110263951 Expired - Fee Related CN102327275B (en) | 2011-09-07 | 2011-09-07 | Application of 3-[4-(sulfonyl)benzene] urea compound in preparation of medicine for tumour |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102327275B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102702057A (en) * | 2012-06-15 | 2012-10-03 | 华东理工大学 | Sulfonamide compound and uses thereof |
US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
CN108794408B (en) * | 2018-07-23 | 2020-04-21 | 中国医科大学 | Pyrimidine phenylurea anti-tumor compound and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010123591A2 (en) * | 2009-01-09 | 2010-10-28 | The Uab Research Foundation | Small molecule inhibitors of nads, namnat, and nmnat |
-
2011
- 2011-09-07 CN CN 201110263951 patent/CN102327275B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010123591A2 (en) * | 2009-01-09 | 2010-10-28 | The Uab Research Foundation | Small molecule inhibitors of nads, namnat, and nmnat |
Non-Patent Citations (1)
Title |
---|
Fabio Pacchiano等.Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis.《J. Med. Chem.》.2011,第54卷1896–1902. * |
Also Published As
Publication number | Publication date |
---|---|
CN102327275A (en) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aggarwal et al. | Update on carbonic anhydrase inhibitors: a patent review (2008–2011) | |
Angeli et al. | Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment | |
Bonardi et al. | Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action | |
Menchise et al. | Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II | |
Pacchiano et al. | Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis | |
Carta et al. | Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo | |
Carta et al. | Sulfonamides and their isosters as carbonic anhydrase inhibitors | |
Nocentini et al. | Discovery of new sulfonamide carbonic anhydrase IX inhibitors incorporating nitrogenous bases | |
Guzel-Akdemir et al. | A class of sulfonamides with strong inhibitory action against the α-carbonic anhydrase from Trypanosoma cruzi | |
Zaib et al. | New aminobenzenesulfonamide–thiourea conjugates: Synthesis and carbonic anhydrase inhibition and docking studies | |
Abdoli et al. | Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo [d] thiazole-5-and 6-sulfonamides | |
M Ghorab et al. | Novel thiourea derivatives bearing sulfonamide moiety as anticancer agents through COX-2 inhibition | |
Shaldam et al. | Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors | |
Awadallah et al. | Inhibition studies on a panel of human carbonic anhydrases with N 1-substituted secondary sulfonamides incorporating thiazolinone or imidazolone-indole tails | |
Zengin Kurt et al. | Synthesis, biological activity and multiscale molecular modeling studies for coumaryl-carboxamide derivatives as selective carbonic anhydrase IX inhibitors | |
Mishra et al. | Design, synthesis and biological evaluation of N-(5-methyl-isoxazol-3-yl/1, 3, 4-thiadiazol-2-yl)-4-(3-substitutedphenylureido) benzenesulfonamides as human carbonic anhydrase isoenzymes I, II, VII and XII inhibitors | |
Boichuk et al. | The design, synthesis, and biological activities of pyrrole-based carboxamides: the novel tubulin inhibitors targeting the colchicine-binding site | |
CN102327275B (en) | Application of 3-[4-(sulfonyl)benzene] urea compound in preparation of medicine for tumour | |
Khan et al. | Quinazolinones as competitive inhibitors of carbonic anhydrase-II (human and bovine): synthesis, in-vitro, in-silico, selectivity, and kinetics studies | |
Sun et al. | Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer | |
Rifati‐Nixha et al. | Synthesis of carbazole bearing pyridopyrimidine‐substituted sulfonamide derivatives and studies their carbonic anhydrase enzyme activity | |
Sepehri et al. | Novel quinazolin–sulfonamid derivatives: synthesis, characterization, biological evaluation, and molecular docking studies | |
Bozdag et al. | Carbonic anhydrase I, II, IV and IX inhibition with a series of 7-amino-3, 4-dihydroquinolin-2 (1H)-one derivatives | |
Aziz et al. | Synthesis, characterization, alkaline phosphatase inhibition assay and molecular modeling studies of 1-benzylidene-2-(4-tert-butylthiazol-2-yl) hydrazines | |
CN102389430B (en) | Application of small molecular compounds to preparation of anti-lung-cancer medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: Suzhou City, Jiangsu province 215137 Xiangcheng District Ji Road No. 8 Patentee after: Soochow University Address before: 215123 Suzhou City, Suzhou Province Industrial Park, No. love road, No. 199 Patentee before: Soochow University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130320 Termination date: 20150907 |
|
EXPY | Termination of patent right or utility model |